Trials / Completed
CompletedNCT03336411
A Personalized Diet Study to Reduce Glycemic Exposure
Personalized Technology-Supported Counseling to Reduce Glycemic Response in Dietary Weight Loss: The Personal Diet Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 269 (actual)
- Sponsor
- NYU Langone Health · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The aim of this 2-phase, randomized clinical trial will be to examine the effects of two behavioral weight loss interventions on weight loss. This study will be conducted in 200 overweight or obese prediabetic individuals recruited from community-based settings.. Phase 1 will include 6-months of active intervention. Phase 2 will consist of 6-months of maintenance and observation. Measurements will occur at screening, baseline, 3, 6, and 12 months. Participants will be randomized with equal allocation to 2 groups: (1) a standardized behavioral weight loss intervention with a one-size-fits-all regimen that includes counseling about restriction of calories and calories from fat, and physical activity, delivered using mHealth technology, or (2) all of the elements of mHealth, plus personalized dietary recommendations to minimize glycemic response to meals. Participants will be required to attend 6 separate visits over both phases of the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | mHealth | Behavioral weight loss intervention using behavioral counseling focusing on physical activity and a one-size-fits-all, calorie-restricted, diet. |
| BEHAVIORAL | Personalized mHealth | Behavioral weight loss intervention with personalized dietary recommendations based on machine learning algorithm that integrates gut microbiota, dietary intake, physical activity and various blood parameters to predict postprandial glycemic response. |
Timeline
- Start date
- 2017-12-12
- Primary completion
- 2021-04-01
- Completion
- 2021-10-27
- First posted
- 2017-11-08
- Last updated
- 2022-03-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03336411. Inclusion in this directory is not an endorsement.